Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Medical Oncology
•
Neurology
What factors do you take into account when deciding the length of adjuvant temozolamide in GBM?
Related Questions
What are your top takeaways in Neuro Oncology from ASCO 2025?
How will you select patients with brain metastases for TTFields?
In what circumstances would you consider use of IDH inhibitors in high-grade astrocytomas?
Do you utilize tumor treating fields in patients with anaplastic pleomorphic xanthoastrocytoma (PXA) III?
What is your management approach for CAR-T induced motor neurologic deficits (cyclophosphamide/IVIG/steroids, etc.) and any prophylactic approach to an early, rapid rise in absolute lymphocyte count post CAR-T infusion?
How would you approach a patient with recurrent grade 3 oligodendroglioma (MGMT-methylated, IDH mutant, 1p/19q co-deleted) 1 year after gross total resection and adjuvant chemotherapy and radiation?
How well does a negative non-contrast MRI of the brain exclude metastasis in a patient with squamous cell carcinoma of the lung?
Are you offering Lutathera for multiple recurrent meningiomas?
Would you consider adding gabapentin off label for use in the treatment of glioblastoma at this time?
How do you counsel glioblastoma multiforme patients on which types of clinical trials to pursue?
